Gamazon, Eric R. http://orcid.org/0000-0003-4204-8734
,
Segrè, Ayellet V. http://orcid.org/0000-0001-6806-5845
van de Bunt, Martijn http://orcid.org/0000-0002-6744-6125
Wen, Xiaoquan
Xi, Hualin S.
Hormozdiari, Farhad http://orcid.org/0000-0002-5617-6174
Ongen, Halit http://orcid.org/0000-0002-4197-5790
Konkashbaev, Anuar
Derks, Eske M. http://orcid.org/0000-0002-6292-6883
Aguet, François http://orcid.org/0000-0001-9414-300X
Quan, Jie
Nicolae, Dan L.
Eskin, Eleazar
Kellis, Manolis
Getz, Gad http://orcid.org/0000-0002-0936-0753
McCarthy, Mark I. http://orcid.org/0000-0002-4393-0510
Dermitzakis, Emmanouil T. http://orcid.org/0000-0002-9302-6490
Cox, Nancy J.
Ardlie, Kristin G.
Article History
Received: 4 July 2017
Accepted: 8 May 2018
First Online: 28 June 2018
Competing interests
: M.I.McC. serves on advisory panels for Pfizer and NovoNordisk. He has received honoraria from Pfizer, NovoNordisk, Sanofi-Aventis, and Eli-Lilly, and research funding from Pfizer, Eli-Lilly, Merck, Takeda, Sanofi Aventis, Astra Zeneca, NovoNordisk, Servier, Janssen, Boehringer Ingelheim, and Roche. M.v.d.B is an employee of Novo Nordisk. H.S.X. and J.Q. are employees of Pfizer.